C. Blajman

3.3k citations
15 papers · 759 indexed · 1 hit paper · h-index 9
Topics
Lung Cancer Treatments and Mutations (8 papers)Cancer Treatment and Pharmacology (7 papers)Advanced Breast Cancer Therapies (3 papers)

In The Last Decade

C. Blajman

15 papers receiving 745 citations

Hit Papers

Cisplatin and fluorouracil with or without panitumumab in...20132026201720212013100200300

Peers

C. Blajman
Comparison fields: 5 of 59
  • Oncology 446
  • Pulmonary and Respiratory Medicine 425
  • Otorhinolaryngology 307
  • Molecular Biology 186
  • Surgery 180
Replace H. Ortíz with:
H. Ortíz United States
Virag Dandekar United States
Arunee Dechaphunkul Thailand
Peter C. Ungaro United States
Xiao-Jing Du China
L. Cals France
H. Koussis Italy
Yalan Tao China
Chi‐Chung Tong China
K. Park South Korea
C. Blajman relative to H. Ortíz United States H. Ortíz's profile →
Citations per field
00.5×10×12.7×
H. Ortíz · 1×
Citations per year

Countries citing papers authored by C. Blajman

Since Specialization
Citations

This map shows the geographic impact of C. Blajman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Blajman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Blajman more than expected).

Fields of papers citing papers by C. Blajman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Blajman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Blajman. The network helps show where C. Blajman may publish in the future.

Co-authorship network of co-authors of C. Blajman

This figure shows the co-authorship network connecting the top 25 collaborators of C. Blajman. A scholar is included among the top collaborators of C. Blajman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Blajman. C. Blajman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
#WorkIndexed citations
1 19
2
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trialbreakdown →
314
3 2
4 179
5 47
6 102
7 19
8
Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer.
1
9 1
10 9
11 2
12 41
13 1
14 19
15
Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer.
3

About C. Blajman

C. Blajman is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine and Oncology, having authored 15 papers that have together received 759 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (8 papers), Cancer Treatment and Pharmacology (7 papers) and Advanced Breast Cancer Therapies (3 papers). The work is most often cited by research in Otorhinolaryngology (307 citations), Oncology (446 citations) and Pulmonary and Respiratory Medicine (425 citations). C. Blajman has collaborated with scholars based in Argentina, United States and Brazil. Frequent co-authors include Eric Winquist, Peter Langmuir, Vera Hirsh, Lisa Licitra, Krzysztof Składowski, Ірина Давиденко, Sandrine Faivre, Yuh‐Min Chen, Laura Emerson and Jin Soo Lee. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026